To evaluate the clinical effectiveness of rcIL-15, the concentration of tumor-related biomarkers, including TK-1, LDH, IFN-γ, and β2M was measured using serum samples and the results are presented in Figure 1. This evidence concerns the gene B2M and neoplasm.